Key result
Extending DAPT lowered the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to aspirin monotherapy.
Why the study?
Does extending DAPT for an additional 12 months reduce cardiovascular events in patients with multivessel coronary artery disease who are event-free after 12 months of DAPT post-PCI?
RCT (n=8,250)
Randomized
Does extending DAPT for an additional 12 months reduce cardiovascular events in patients with multivessel coronary artery disease who are event-free after 12 months of DAPT post-PCI?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Shortening DAPT is absolutely appropriate when the recurrent ischemic event risk is low and/or the bleeding risk is high. What this study demonstrates is that when the opposite is true, that is, when the recurrent ischemic event rate is high and the bleeding risk is low, extending DAPT can prove beneficial even in the modern era of contemporary stenting. Every patient has got to be individualized for their relative risks of recurring ischemia and bleeding.”
“beyond its direct antithrombotic effects, inhibition of the adenosine diphosphate receptor during the second year after an acute coronary syndrome – a high-risk period for plaque progression – may stabilize untreated vulnerable plaques, a beneficial effect that may persist after its discontinuation.”
“Nevertheless, the identification of a specific population with high ischemic risk but low bleeding risk that can benefit from extended DAPT is a step forward in our field.”
Extending DAPT with clopidogrel and aspirin beyond 12 months reduces ischemic events in post-PCI patients with multivessel disease who tolerated the first 12 months without events.
To the Editor: Tian and colleagues (July 16 issue) 1 assess whether patients with multivessel coronary artery disease who had been event-free while receiving dual antiplatelet therapy (DAPT) for 12 months after percutaneous coronary intervention (PCI) may benefit from extending DAPT. In the Dual Antiplatelet Therapy in Patients with Coronary Multivessel Disease (DAPT-MVD) trial, 8250 patients were randomly assigned to continue DAPT (clopidogrel plus aspirin) or receive aspirin monotherapy for 12 months. Extending DAPT led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (the composite primary efficacy end point) without increasing the risk of . . .
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted an RCT in Multivessel coronary artery disease (n=8,250). Extended DAPT (clopidogrel plus aspirin) vs. Aspirin monotherapy was evaluated on Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Extending DAPT lowered the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to aspirin monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: